Armata achieved a major milestone with positive topline results from its Phase 1b/2a clinical trial of AP-SA02 for Staphylococcus aureus bacteremia. These 10 stocks could mint the next wave of ...

An update from Armata Pharmaceuticals ( ($ARMP) ) is now available. On August 11, 2025, Armata Pharmaceuticals entered into a secured credit ...

Advancement of modular therapies offers a new dynamic for today’s patients, but there’s still a need to maintain infection ...

Point-of-care testing, new treatments, and antimicrobial stewardship could hold promise for future control of antibiotic resistance.